Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine and Cytarabine for Persistent AML
NCT01960387Phase 2Terminated
- Sponsor
- University of Pittsburgh
- Start
- Oct 2013
- Primary completion
- Mar 2015
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clofarabine in acute myeloid leukemia (AML), sponsored by University of Pittsburgh. Primary endpoint: Complete Clinical Response. Started Oct 2013; status: terminated.
02
Drugs
clofarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01960387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01960387.